5-sec-butyl-1,3-dihydro-benzimidazol-2-one | 99840-58-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-sec-butyl-1,3-dihydro-benzimidazol-2-one
• 英文别名: 5-sec-Butyl-1,3-dihydro-benzimidazol-2-on；2-Benzimidazolinone, 5-sec-butyl-；5-butan-2-yl-1,3-dihydrobenzimidazol-2-one
• CAS: 99840-58-1
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: MUXWSFCUYVIPIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• [EN] METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS<br/>[FR] MÉTHODES ET COMPOSITIONS POUR CIBLER DES TREG AU MOYEN D'INHIBITEURS DE CCR8
  申请人：NANJING IMMUNOPHAGE BIOTECH CO LTD

  公开号：WO2022000443A1

  公开（公告）日：2022-01-06

  Provided herein are compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

  本文提供的是Formula (I)的化合物，可用作CCR8抑制剂，可用作使用CCR8抑制剂靶向肿瘤特异性T调节细胞的癌症治疗或预防。
• Tetrahydropyrazolopyrimidine compounds
  申请人：EISAI R&D MANAGEMENT CO., LTD.

  公开号：US10640500B2

  公开（公告）日：2020-05-05

  Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

  本公开的实施方案涉及作为Toll样受体7和/或8的拮抗剂或抑制剂的四氢吡唑嘧啶化合物，以及它们在有效治疗系统性红斑狼疮（SLE）和狼疮肾炎的药物组合物中的用途。
• ACETYL COENZYME A CARBOXYLASE INHIBITORS
  申请人：Chang Edcon

  公开号：US20090005375A1

  公开（公告）日：2009-01-01

  The present invention relates to acetyl coenzyme-A carboxylase (“ACC”) inhibiting compounds of the formula wherein the variables are as defined herein. In particular, the present invention relates to ACC1 and/or ACC2 inhibitors, compositions of matter, kits and articles of manufacture comprising these compounds, methods for inhibiting ACC1 and/or ACC2, and methods of making the inhibitors.
• AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20200339581A1

  公开（公告）日：2020-10-29

  Disclosed are compounds of Formula (I) or salts thereof, wherein G, R1, R5, R7, R8, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
• SOMATOSTATIN MODULATORS AND USES THEREOF
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US20210171492A1

  公开（公告）日：2021-06-10

  Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.